ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related Disease
Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission improved with inebilizumab
Oral Infigratinib Seems Safe for Children With Achondroplasia
At dose of 125 mg/kg body weight, oral infigratinib results in increased annualized height velocity and z score
Beta Blockers May Cause Depressive Symptoms
Findings seen in patients following myocardial infarction
ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer
One-year progression-free survival, overall survival was 79.4, 89.6 percent; significantly longer survival seen in patients who achieved resectability
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
Three years of tirzepatide also reduced risk for progression to type 2 diabetes compared with placebo
Bleeding Risk Increased With NSAID Use for VTE Patients Receiving Anticoagulants
More than twofold increased bleeding rate seen with NSAID use for patients treated with oral anticoagulants for VTE
Global Coverage With Measles Vaccine Declined During COVID-19
From 2022 to 2023, there was a 20 percent increase in estimated measles cases worldwide, from 8,645,000 to 10,341,000
Metformin Use Tied to Lower Rate of Asthma Attacks
Further reductions seen with the use of glucagon-like peptide-1 receptor agonists
Gabapentinoid Use Tied to Higher Risk for Hip Fractures
Associations especially strong in patients who are frail or have chronic kidney disease
FDA Approves Cobenfy for Adults With Schizophrenia
Approval marks first new class of treatment in decades and the first muscarinic agonist
